Abbott Laboratories (ABT) Cost of Revenue (2009 - 2026)

Abbott Laboratories (ABT) has 18 years of Cost of Revenue data on file, last reported at $4.9 billion in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 9.44% year-over-year to $4.9 billion; the trailing twelve-month figure through Mar 2026 stood at $19.7 billion (up 5.5% YoY), and the FY2025 full-year result was $19.3 billion, up 3.28% from the prior year.
• Cost of Revenue retreated to $4.9 billion in Q1 2026, from $4.9 billion in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $5.1 billion in Q3 2025 to a low of $4.3 billion in Q1 2023.
• A 5-year average of $4.7 billion and a median of $4.6 billion in 2022 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue rose 13.32% in 2022 and retreated 13.15% in 2023, its largest moves.
• Tracing ABT's Cost of Revenue over 5 years: stood at $4.6 billion in 2022, then declined by 0.81% to $4.6 billion in 2023, then advanced by 8.47% to $4.9 billion in 2024, then slipped by 0.4% to $4.9 billion in 2025, then decreased by 0.65% to $4.9 billion in 2026.
• Business Quant data shows ABT's Cost of Revenue at $4.9 billion in Q1 2026, $4.9 billion in Q4 2025, and $5.1 billion in Q3 2025.